Brokerages Set Oxford Biomedica plc (LON:OXB) Target Price at GBX 600.04

Oxford Biomedica plc (LON:OXB) has been assigned an average recommendation of “Buy” from the six research firms that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued ratings on the stock in the last year is GBX 633.38.

Several brokerages have recently weighed in on OXB. Royal Bank Of Canada lowered their target price on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating on the stock in a report on Wednesday, June 24th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd.

Oxford Biomedica Stock Down 0.5%

Shares of LON OXB opened at GBX 605 on Tuesday. The stock has a market cap of £732.27 million, a PE ratio of -22.47 and a beta of 1.12. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. Oxford Biomedica has a 12-month low of GBX 356 and a 12-month high of GBX 952. The company has a 50-day moving average of GBX 615.78 and a 200 day moving average of GBX 664.77.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.